The World Health Organization and the pharmaceutical industry: Common areas of interest and differing views

Adverse Drug Reactions and Toxicological Reviews

Volumn 21, Issue 1-2, 2002, Pages 51-99

  Hardwicke, Caroline J ^a  

^a NONE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMODIAQUINE; AMPHOTERICIN B DEOXYCHOLATE; ANTIBIOTIC AGENT; ANTIMALARIAL AGENT; ARTEMETHER PLUS BENFLUMETOL; ARTEMISIN DERIVATIVE; ARTESUNATE; ATOVAQUONE PLUS PROGUANIL; AZITHROMYCIN; CERIVASTATIN; CHLOROQUINE; CHLORPHENIRAMINE; COTRIMOXAZOLE; DENGUE VACCINE; DIDANOSINE; EFLORNITHINE; FANSIDAR; GENERIC DRUG; HALOFANTRINE; HISTAMINE H1 RECEPTOR ANTAGONIST; MEFLOQUINE; MEGESTROL ACETATE; MELARSOPROL; NEVIRAPINE; PENTAMIDINE; STAVUDINE; SURAMIN; TETRAVALENT VACCINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZIDOVUDINE;

CANCER; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DECISION MAKING; DEVELOPING COUNTRY; DRUG CLASSIFICATION; DRUG COST; DRUG DEVELOPMENT; DRUG INDUSTRY; DRUG LEGISLATION; DRUG MARKETING; DRUG QUALITY; DRUG RESEARCH; DRUG SAFETY; FINANCIAL MANAGEMENT; GEOGRAPHIC DISTRIBUTION; GREENHOUSE EFFECT; HEALTH CARE POLICY; HERBAL MEDICINE; HUMAN; INFECTION; MEDICAL INFORMATION SYSTEM; NONHUMAN; PATENT; POLITICS; POVERTY; PUBLIC RELATIONS; REVIEW; SELF MEDICATION; TRADITIONAL MEDICINE; TROPICAL DISEASE; WORLD HEALTH ORGANIZATION; LEGAL ASPECT;

ARTESUNATE;

DEVELOPING COUNTRIES; DRUG INDUSTRY; FUND RAISING; HUMANS; WORLD HEALTH ORGANIZATION;

EID: 0035984737     PISSN: 0964198X     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03256183     Document Type: Review

References (151)

1. Aventis puts 25% target on growth
2. Drug firms are not the villains
3. Oxfam urges charitable stance on drugs patent
4. Essential drugs
5. Drug giants remain addicted to high profit margins
6. Glaxo promises another £250 million of cuts
7. An epidemic of dengue 3 in far north Queensland, 1997-1999
8. Developing a global strategy for cancer
9. WONCA and the pharmaceutical industry: World Organisation of National Colleges, Academies and Academic Associations of General Practice/Family Medicine
10. Developing a global strategy for cancer
11. Laboratories which procedure veterinary vaccines
12. Is there an industrial future for phytopharmaceutical drugs?. An outline of UNIDO programmes in the sector
13. Activities of the International Federation of Pharmaceutical Manufacturers Associations in world health
14. WHO's malaria program Roll Back Malaria
15. WHO's mission in essential drugs and medicines policy
16. Essential Drugs & Medicines Policy; WHO Medicines in the World Organization, Structure and Policy
17. WHO Budget 1998-99
18. Global pharma sales in 2000 up 10%
19. Small setback for world pharma growth
20. The impact of liability and cost containment on the drug development process
21. Serono to double external research spending
22. The impact of regulation on new drug development
23. The evolving drug discovery and development process
24. Doctors call for more pharmacogenetic studies
25. Pharmacogenetics and future drug development and delivery
26. Patenting proteins for personalised medicines
27. Decision points in human drug development
28. MSF Briefing for the 54th World Health Assembly 2000
29. Sources and prices of selected drugs and diagnostics for people living with HIV/AIDS
30. Activists hit out at WHO's private sector deals
31. Time to drop the 'them-and-us' approach?
32. Drug treatment of tropical parasitic infections
33. Putting the partnerships into public-private partnerships
34. Co-operation comes to the fore in 1998
35. Planning
36. Preclinical toxicity testing
37. Making drugs into medicines
38. The current rules for conducting clinical research
39. Guidelines for Good Clinical Practice (GCP) for trials on pharmaceutical products
40. Thalidomide and congenital abnormalities
41. Tufts center pegs cost of a new prescription medicine at $802 million
42. International nonproprietary names. EDM Department
43. Legal and ethical issues concerning pharmaceutical products
44. Agreement on trade-related aspects of intellectual property rights (TRIPS agreement), 1994
45. New UN agency examines patent protection for traditional knowledge
46. Intellectual property: Patents and pharmaceuticals
47. TRIPS, pharmaceuticals and developing countries: Implications for health care access, drug quality and drug development
48. Globalisation and access to drugs. Implications of the WTO/TRIPS agreement
49. Developing countries warned against patent treaty
50. New Kenyan bill allows parallel imports
51. South Africa's moral victory
52. 'Cipla not a pirate' and 'Cuba offers generic HIV/AIDS drugs'. World news in brief
53. Cameroon and Mali sign deals for cheaper AIDS drugs. Medicines access news in brief
54. The value and benefits of ICH to industry
55. Press release of the ICH Steering Committee Meeting; Chiba, Japan, 2001 May 21-24
56. General policy issues. Global harmonisation and the ICH
57. The safety of medicines
58. Notice to marketing authorisation; Pharmacovigilance guidelines CPMP/PhVWP/108/99
59. The WHO Collaborative Centre for International Drug Monitoring (Uppsala)
60. Information and promotion
61. Self-regulation of marketing practices
62. IFPMA code of pharmaceutical marketing practices
63. The health care implications of international price differences. IFPMA Advisory Committee on Trade and Economics, 2000
64. IFPMA support for EDL
65. Manufacturing issues hit Schering-Plough
66. Use of the WHO certification scheme on the quality of pharmaceutical products moving in international commerce
67. Quality assurance of medicines
68. Action urged on world-wide problem of counterfeit medicines
69. Self-medication with zidovudine that was not
70. Counterfeit drugs: Guidelines for the development of measures to combat counterfeit drugs
71. Counterfeiting of medicinal products
72. General policy issues. Generic drugs: The hidden issues of quality and cost
73. The 'essential drug' concept
74. The role of generics
75. Most US drug donations 'relevant', claims new industry-funded study
76. The partnership for quality medical donations
77. Prevalence of use of complementary/alternative medicine: A systematic review
78. The regulation of herbal products in Europe: From diversity to harmonisation?
79. Herbal medicine heads for the mainstream
80. Chinese herb may cause cancer
81. General policy issues. The benefits and risks of self-medication
82. Herbal medicines. Research and evaluation of traditional and herbal medicines
83. Guidelines for the regulatory assessment of medicinal products for use in self-edication
84. Price we could pay for global warming
85. Uncertain impact of global warming on disease
86. The fall and rise of sleeping sickness
87. Risk factors for encephalopathy and mortality during melarsoprol treatment of Trypanosoma brucei gambiense sleeping sickness
88. Duration of symptoms and case fatality of sleeping sickness caused by Trypanosoma brucei rhodesiense in Tororo, Uganda
89. Chemotherapeutically active nitro compounds. 4, 5-Nitroimidazoles
90. Combination chemotherapy of CNS trypanosomiasis
91. BMS brokers sleeping sickness deal
92. Aventis press release
93. Africa, apathy and antimalarials
94. Plasmodium falci parum resistance to sulfadoxine/pyrimethamine in Uganda: Correlation with polymorphisms in the dihydrofolate reductase and dihydropteroate synthetase genes
95. Increased carriage of the trimethoprim/sulfamethoxazole resistant Streptococcus pneumoniae in Malawian children after treatment for malaria with sulfadoxine/pyrimethamine
96. Sustainability, affordability and equity of corporate drug donations: The case of Malarone®
97. Comparative efficacy of chloroquine/chlorpheniramine combination and mefloquine for the treatment of chlorquine-resistant Plasmodium falciparum malaria in Nigerian children
98. Effect of chlorpheniramine on the pharmacokinetics of and response to chloroquine of Nigerian children with falciparum malaria
99. Comparative efficacy of chloroquine plus chlorpheniramine and pyrimethamine/sulfadoxine in acute uncomplicated falciparum malaria in Nigerian children
100. Novartis to supply antimalarial at cost
101. MMV looks for new malaria projects
102. Structural initiatives take aim at malaria
103. GSK starts paediatric malaria trials
104. Dengue: Emergence as a global public health problem and prospects for control
105. Dengue viral infections: Pathogenesis and epidemiology
106. Live attenuated tetravalent dengue vaccine
107. Yellow fever: A decade of reemergence
108. Impact of yellow fever on the developing world
109. Financial crisis hits vaccination plans
110. Polio eradication campaign is on track
111. Global trends in resistance to antituberculosis drugs
112. World health report on infectious diseases
113. Resistance due to no new antibiotics
114. Antex discovers new antibiotic class
115. New drug candidate for TB
116. Mexican indigenous medicines explored
117. Indian community profits from herbals
118. Boehringer to scan natural libraries
119. Phytopharm targets colon cancer
120. Curing cancer with clover
121. Traditional Indian medical knowledge for sale
122. Treating HIV in South Africa: A tale of two systems
123. Malarone donation programme to end on completion of the pilot phase
124. It is appropriate to create new pharmaceutical products within developing countries